JAMA psychiatry
-
Randomized Controlled Trial Multicenter Study
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. ⋯ In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related. Response appeared to persist for more than 2 months with a lower dosing frequency. Results support further investigation in larger trials.